Provided by Tiger Trade Technology Pte. Ltd.

EyePoint

3.45
-0.2100-5.74%
Post-market: 3.500.0500+1.45%16:54 EDT
Volume:4.96M
Turnover:17.56M
Market Cap:297.43M
PE:-0.92
High:3.74
Open:3.66
Low:3.42
Close:3.66
52wk High:19.11
52wk Low:3.42
Shares:86.21M
Float Shares:60.67M
Volume Ratio:1.51
T/O Rate:8.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7642
EPS(LYR):-3.1667
ROE:-148.70%
ROA:-74.85%
PB:1.79
PE(LYR):-1.09

Loading ...

EyePoint grants inducement stock options for 158,100 shares at $12.35 each

Reuters
·
May 18

EyePoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 18

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
May 18

EyePoint receives positive DSMC recommendation for Duravyu Phase 3 trials

TIPRANKS
·
May 14

EyePoint's late-stage eye drug trials to continue after safety panel review

Reuters
·
May 14

EyePoint Pharmaceuticals Says Phase 3 Eye Drug Trials Clear Safety Review

MT Newswires Live
·
May 14

EyePoint Advances DURAVYU Phase 3 Wet AMD Program

TIPRANKS
·
May 14

EyePoint Inc - Dsmc Recommends Phase 3 Duravyu Wet Amd Trials Continue With No Modifications

THOMSON REUTERS
·
May 14

EyePoint Inc - Interim Phase 3 Data Shows Continued Favorable Safety Profile for Duravyu

THOMSON REUTERS
·
May 14

EyePoint Announces Third Consecutive Positive Dsmc Recommendation for Phase 3 Wet Amd Trials for Duravyu™, Building Confidence Ahead of Mid-2026 Topline Data

THOMSON REUTERS
·
May 14

EyePoint Pharmaceuticals Is Maintained at Outperform by RBC Capital

Dow Jones
·
May 08

RBC Capital Adjusts EyePoint Pharmaceuticals PT to $37 From $39, Maintains Outperform Speculative-Risk Rating

MT Newswires Live
·
May 07

EyePoint Pharmaceuticals (EYPT) Gets a Buy from Guggenheim

TIPRANKS
·
May 07

EyePoint reports Q1 EPS (99c), consensus (81c)

TIPRANKS
·
May 07

Analysts Are Bullish on These Healthcare Stocks: EyePoint Pharmaceuticals (EYPT), BeOne Medicines (ONC)

TIPRANKS
·
May 07

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT) and 908 Devices (MASS)

TIPRANKS
·
May 07

EyePoint Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 06

Earnings Flash (EYPT) EyePoint Posts Q1 Loss $0.99 a Share, vs. FactSet Est of $0.79 Loss

MT Newswires Live
·
May 06

EyePoint Pharmaceuticals Q1 net loss widens on increased R&D spending

Reuters
·
May 06

EyePoint Q1 FY26 net loss widens to $84.8 million; revenue drops to $0.7 million

Reuters
·
May 06